Skip to main content
Premium Trial:

Request an Annual Quote

Berry Oncology Raises $99.2M in Series B1 Round

NEW YORK — Berry Oncology said on Thursday that it has closed a $99.2 million Series B1 round of financing.

The round was led by China Merchants Capital Management and included existing investors Qiming Venture Partners and Legend Capital, as well as new investors Zhongjin Qichen Industry Equity Investment Fund, E Fund, Fujian Venture Investment Management, and Xiamen C&D Emerging Industry Equity Investment.

Berry Oncology, a subsidiary of Beijing-based Berry Genomics, said it has raised $309 million since its inception in 2017. The company offers cancer screening tests including Lai Si Ning, a next-generation sequencing-based assay for liver cancer, and maintains sites in Fuzhou and Beijing. It has been working with more than 700 hospitals across China and has provided genomic testing services for hundreds of thousands of cancer patients.

Earlier this year, Berry Oncology partnered with Alibaba Health, a division of Chinese technology firm Alibaba Group, to develop an early cancer screening and healthcare platform.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.